Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04209049 · ClinicalTrials.gov registry record · Phase 1
A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT04209049 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 33 participants.
The verdict
NCT04209049, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The study looks at the blood levels of a new study medicine in people with normal and impaired kidney function. Participants will get the study medicine called NNC0174-0833. This is an experimental medicine and has not been approved by the US FDA. It is being developed as a new medicine for weight management. Participants will get 1 injection of the study medicine by a study nurse at the clinic. The injection will be with a needle in a skin fold in the stomach area. The study will last for about 9 weeks. Participants will have about 7 visits with the study staff or the doctor. At the visits, participants will have clinical checks done and blood samples taken. Participants will be collecting their urine several times during the study. Participants will be asked about their health, medical history and habits. People who are already in another research study cannot take part. Only women who are not able to become pregnant can take part in the study. Only men who do not plan to father a child during the study or 6 weeks following the dose administration can take part in the study.
Interventions
- DRUG NNC0174-0833
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04209049
The ClinicalTrials.gov registry entry for NCT04209049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NNC0174-0833 is the first listed.
NCT04209049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04209049 about?
NCT04209049 is a clinical study titled "A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function". The study looks at the blood levels of a new study medicine in people with normal and impaired kidney function. Participants will get the study medicine called NNC0174-0833. This is an experimental medicine and has not been approved by the US FDA. It is being developed as a new medicine for weight m...
What is the current status of trial NCT04209049?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2020-01-15. Estimated completion is 2021-01-05.
What interventions are being tested in trial NCT04209049?
The interventions under investigation include: NNC0174-0833 (DRUG).
Who is sponsoring clinical trial NCT04209049?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.